Novartis AG (NYSE: NVS) announced Monday that it is adding to its immunomodulatory medicine portfolio with with an acquisition. What Happened Novartis said it's acquiring IFM Tre, a subsidiary of IFM ...
Novartis is handing over $310 million up front to acquire IFM Therapeutics’ inflammation-centered subsidiary, IFM Tre. The deal includes up to $1.265 billion in milestones and gives Novartis access to ...
Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...
ZURICH (Reuters) - Novartis on Monday said it had agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results